Vyne Therapeutics Inc (VYNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Sales | 178 | 273 | 133 | 295 | 230 |
| Gross Profit | 178 | 273 | 133 | 295 | 230 |
| Operating Expenses | 8,869 | 9,118 | 10,900 | 9,837 | 9,987 |
| Operating Income | -8,691 | -8,845 | -10,767 | -9,542 | -9,757 |
| Interest Expense | 0 | 0 | 3,474 | 1,074 | 1,062 |
| Other Income | -3 | 26 | -35 | -69 | -57 |
| Pre-tax Income | -8,694 | -8,819 | -14,276 | -10,685 | -10,876 |
| Net Income Continuous | -8,694 | -8,371 | -14,276 | -10,685 | -10,876 |
| Net Income Discontinuous | 13,364 | -3,199 | -7,009 | -9,239 | -9,674 |
| Net Income | $4,670 | $-11,570 | $-21,285 | $-19,924 | $-20,550 |
| EPS Basic Total Ops | 1.51 | -3.70 | -7.37 | -7.01 | -7.55 |
| EPS Basic Continuous Ops | -2.83 | -2.87 | -4.86 | -3.78 | -3.96 |
| EPS Basic Discontinuous Ops | 4.34 | -0.83 | -2.52 | -3.24 | -3.60 |
| EPS Diluted Total Ops | 1.51 | -3.70 | -7.37 | -7.01 | -7.55 |
| EPS Diluted Continuous Ops | -2.83 | -3.23 | -4.86 | -3.78 | -3.60 |
| EPS Diluted Discontinuous Ops | 4.34 | -0.83 | -2.52 | -3.24 | -3.60 |
| EBITDA(a) | $-8,647 | $-8,819 | $-10,739 | $-9,514 | $-9,730 |